GlassScriptPhysician profile
Lynnette M Atkinson
NPI 1366870792
$1,891.43
in general payments reported to CMS, 2019-2025
27 companies · $697 in 2025
The $697 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $302 · 2022: $127 · 2023: $267 · 2024: $499 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,462.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $404.95 | 2021-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.77 | 2021-2025 | Ofev |
| Insmed, INC. | $138.39 | 2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $124.38 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $119.33 | 2021-2025 | Fasenra, Breztri, Airsupra |
| Amgen INC. | $118.16 | 2023-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $92.23 | 2021-2023 | Dupixent |
| Grifols USA, LLC | $82.01 | 2021-2023 | Prolastin-C Liquid |
| Inspire Medical Systems, INC. | $63.44 | 2025 | Inspire |
| Boston Scientific Corporation | $60.86 | 2021-2022 | |
| Medtronic, INC. | $59.11 | 2024 | Stealthstation S8 Platform |
| Actelion Pharmaceuticals US, INC. | $46.26 | 2021 | |
| Harmony Biosciences LLC | $46.26 | 2025 | |
| United Therapeutics Corporation | $44.67 | 2023-2024 | Tyvaso |
| Pulmonx Corporation | $34.56 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $29.13 | 2024 | Glassia |
| Verona Pharma, INC. | $28.06 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $28.05 | 2021 | |
| Fisher & Paykel Healthcare INC | $24.69 | 2025 | Fisher & Paykel Healthcare |
| Jazz Pharmaceuticals INC. | $23.70 | 2021 | |
| Axsome Therapeutics, INC. | $22.31 | 2023 | Sunosi |
| Bayer Healthcare Pharmaceuticals INC. | $21.91 | 2024 | |
| Mallinckrodt Hospital Products INC. | $21.82 | 2024 | Acthar |
| Zoll Respicardia, INC. | $21.17 | 2025 | Remede System |
| Electromed, INC. | $19.62 | 2025 | Smartvest |
| Mylan Specialty L.P. | $17.70 | 2023 | Yupelri |
| Resmed Corp | $16.89 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynnette Atkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.